Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Consolidated Net Income: 2009-2024

Historic Consolidated Net Income for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to -$14.0 million.

  • Heron Therapeutics' Consolidated Net Income rose 8.19% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 106.16%. This contributed to the annual value of -$14.0 million for FY2024, which is 87.39% up from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Consolidated Net Income is -$14.0 million, which was up 87.39% from -$111.1 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Consolidated Net Income ranged from a high of -$14.0 million in FY2024 and a low of -$226.4 million during FY2020.
  • For the 3-year period, Heron Therapeutics' Consolidated Net Income averaged around -$100.2 million, with its median value being -$111.1 million (2023).
  • In the last 5 years, Heron Therapeutics' Consolidated Net Income decreased by 10.50% in 2020 and then soared by 87.39% in 2024.
  • Over the past 5 years, Heron Therapeutics' Consolidated Net Income (Yearly) stood at -$226.4 million in 2020, then increased by 2.93% to -$219.8 million in 2021, then rose by 20.16% to -$175.5 million in 2022, then soared by 36.68% to -$111.1 million in 2023, then soared by 87.39% to -$14.0 million in 2024.